At Webrivaig.com, we recognize that privacy of your personal information is important. Here is information on what types of personal information we receive and collect when you use and visit Webrivaig.com, and how we safeguard your information. We never sell your personal information to third parties.
As with most other websites, we collect and use the data contained in log files. The information in the log files include your IP (internet protocol) address, your ISP (internet service provider, such as AOL or Shaw Cable), the browser you used to visit our site (such as Internet Explorer or Firefox), the time you visited our site and which pages you visited throughout our site.
We do use cookies to store information, such as your personal preferences when you visit our site. This could include only showing you a popup once in your visit, or the ability to login to some of our features, such as forums.
We also use third party advertisements on Webrivaig.com to support our site. Some of these advertisers may use technology such as cookies and web beacons when they advertise on our site, which will also send these advertisers (such as Google through the Google AdSense program) information including your IP address, your ISP , the browser you used to visit our site, and in some cases, whether you have Flash installed. This is generally used for geotargeting purposes (showing New York real estate ads to someone in New York, for example) or showing certain ads based on specific sites visited (such as showing cooking ads to someone who frequents cooking sites).
To comply with the GDPR you need to be made aware that your Webrivaig.com account will, at a bare minimum, contain a uniquely identifiable name (hereinafter “your user name”), a personal password used for logging into your account (hereinafter “your password”) and a personal, valid email address (hereinafter “your email”). Your information for your account at Webrivaig.com is protected by data-protection laws applicable in the country that hosts us. Any information beyond your user name, your password, and your email address required by Webrivaig.com during the registration process is either mandatory or optional, at the discretion of Webrivaig.com. In all cases, you have the option of what information in your account is publicly displayed. Furthermore, within your account, you have the option to opt-in or opt-out of automatically generated emails.
Furthermore we will store all of the IP address that you use to post with. Depending on your preferences Webrivaig.com may send you emails to the email address that Webrivaig.com holds in your account which will either be that you used when you registered or one that you have subsequently changed, but you are able to change these preferences from your User Control Panel (UCP) at any time should you wish to stop receiving them.
The personal details that you gave us when you signed up, or added later, will be used solely for the purposes of Webrivaig.com board functionality. They will not be used for anything else and neither will they be passed on to any third party without your explicit consent. You can check, at any time, the personal details Webrivaig.com is holding about you from the Profile section of your UCP.
The only other information about you is that which you decide to post in the forum, whereupon it is considered to be “publicly available” to other registered members and please note, Webrivaig.com does not allow the forum content to be indexed by search engines or to be allowed on any on-line archive sites and these search engines and/or on-line archive sites should follow our rules.
The advent of artificial intelligence (AI) in healthcare is heralding a new epoch, particularly in the realm of breast cancer screening. A prime example of this technological evolution is Mia, an AI tool developed for the NHS, which has shown exceptional promise in identifying early indicators of breast cancer missed by traditional screening methods. Through the analysis of over 10,000 mammograms, Mia not only reaffirmed existing diagnoses but also brought to light 11 cases that had gone unnoticed by healthcare professionals.